Zentalis Q1 net loss narrows to $35.35 million; operating loss improves to $37.86 million

• Zentalis Pharmaceuticals reported a net loss of USD 35.35 million for the quarter ended March 31, 2026, narrowing from USD 48.28 million a year earlier.
• Operating loss improved to USD 37.86 million from USD 45.62 million, while research and development expense edged up 5.39% to USD 28.72 million.
• General and administrative costs fell 13.62% to USD 9.14 million, while investment and other income swung to USD 2.62 million from a loss of USD 2.66 million.
• Cash, cash equivalents and marketable securities totaled USD 211.8 million, with funding expected to last into late 2027.
• Pipeline updates included selection of a 400 mg QD 5:2 pivotal monotherapy dose in DENALI Part 2, first patient dosed in Phase 3 ASPENOVA, with DENALI Part 2 topline data expected by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001725160-26-000042), on May 12, 2026, and is solely responsible for the information contained therein.